

Konstantin Kazankov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6276920/publications.pdf>

Version: 2024-02-01

30
papers

1,562
citations

567281

15
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

2679
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass. <i>Physiological Reports</i> , 2022, 10, e15157.	1.7	3
2	Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 51-64.	3.0	8
3	Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nationwide Cohort Study. <i>Hepatology</i> , 2021, 74, 2725-2734.	7.3	16
4	Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2020, 27, 28-35.	2.0	36
5	Macrophage markers and innate immunity in cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 1586-1588.	3.7	8
6	Early normalization of reduced urea synthesis capacity after direct-acting antiviral therapy in hepatitis C cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G151-G156.	3.4	2
7	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2
8	Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. <i>Frontiers in Medicine</i> , 2020, 7, 615599.	2.6	19
9	Liver-related effects of chronic hepatitis C antiviral treatment. <i>World Journal of Gastroenterology</i> , 2020, 26, 2931-2947.	3.3	11
10	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	3.7	128
11	QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascites. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1376-1378.	1.5	2
12	Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 623-632.	1.5	7
13	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. <i>World Journal of Hepatology</i> , 2019, 11, 138-149.	2.0	122
14	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 145-159.	17.8	571
15	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 484-491.	2.8	27
16	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 67, 635-642.	1.8	10
17	Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 986-993.	1.5	23
18	Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 498-504.	1.2	26

#	ARTICLE	IF	CITATIONS
19	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 308-316.	0.9	0
20	High burden of coronary atherosclerosis in patients with cirrhosis. <i>European Journal of Clinical Investigation</i> , 2017, 47, 565-573.	3.4	14
21	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 321-348.	0.1	1
22	The macrophage activation marker <sc>CD</sc>163 is associated with morphological disease stages in patients with non- α alcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1549-1557.	3.9	94
23	Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 64-73.	1.2	29
24	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2016, , 1-28.	0.1	2
25	Reply. <i>Hepatology</i> , 2015, 61, 735-736.	7.3	4
26	Macrophage activation marker soluble <sc>CD</sc>163 and non- α alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1293-1300.	2.8	53
27	Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. <i>PLoS ONE</i> , 2015, 10, e0137302.	2.5	54
28	Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. <i>Hepatology</i> , 2014, 60, 521-530.	7.3	150
29	Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. <i>Gut</i> , 2013, 62, 1231-1232.	12.1	40
30	Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. <i>Liver International</i> , 2011, 31, 534-540.	3.9	100